Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA Jr, Chan DC, Pallansch P, Eckhardt SG. Witta SE, et al. Among authors: eckhardt sg. Clin Cancer Res. 2004 Nov 1;10(21):7229-37. doi: 10.1158/1078-0432.CCR-03-0181. Clin Cancer Res. 2004. PMID: 15534096 Clinical Trial.
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Gore L, Holden SN, Cohen RB, Morrow M, Pierson AS, O'Bryant CL, Persky M, Gustafson D, Mikule C, Zhang S, Palmer PA, Eckhardt SG. Gore L, et al. Among authors: eckhardt sg. Ann Oncol. 2006 Nov;17(11):1709-17. doi: 10.1093/annonc/mdl282. Epub 2006 Sep 15. Ann Oncol. 2006. PMID: 16980604 Free article. Clinical Trial.
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG. Basche M, et al. Among authors: eckhardt sg. Clin Cancer Res. 2006 Sep 15;12(18):5471-80. doi: 10.1158/1078-0432.CCR-05-2423. Clin Cancer Res. 2006. PMID: 17000682 Clinical Trial.
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG. Hariharan S, et al. Among authors: eckhardt sg. Ann Oncol. 2007 Aug;18(8):1400-7. doi: 10.1093/annonc/mdm140. Ann Oncol. 2007. PMID: 17693653 Free article. Clinical Trial.
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello F, Eckhardt SG. Troiani T, et al. Among authors: eckhardt sg. Clin Cancer Res. 2007 Nov 1;13(21):6450-8. doi: 10.1158/1078-0432.CCR-07-1094. Clin Cancer Res. 2007. PMID: 17975157
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
Zerbe LK, Dwyer-Nield LD, Fritz JM, Redente EF, Shroyer RJ, Conklin E, Kane S, Tucker C, Eckhardt SG, Gustafson DL, Iwata KK, Malkinson AM. Zerbe LK, et al. Among authors: eckhardt sg. Cancer Chemother Pharmacol. 2008 Sep;62(4):605-20. doi: 10.1007/s00280-007-0644-z. Epub 2007 Nov 21. Cancer Chemother Pharmacol. 2008. PMID: 18030469
362 results